In addition, complementary to the reported synthetic lethality of targeting p300 in CREBBP-mutant cancer cells (84), the synthetic lethality of targeting CBP in EP300-mutant cases offers a potential alternative therapeutic opportunity for these patients. This evidence concerns the gene CREBBP and cancer.